Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid class, structurally related to ibuprofen, fenoprofen, and ketoprofen. It is used primarily for the symptomatic treatment of osteoarthritis and rheumatoid arthritis, providing relief from pain, inflammation, swelling, stiffness, and joint pain. Flurbiprofen acts as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation and pain. It is available as an oral tablet for systemic use and also in ophthalmic formulations for prevention or reduction of intraoperative miosis during ocular surgery. The S-enantiomer has both anti-inflammatory and antinociceptive effects via inhibition of prostaglandin biosynthesis; R-flurbiprofen exhibits antinociceptive activity but not significant anti-inflammatory action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flurbiprofen.